The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
This past week, following the FDA’s decision to issue a partial clinical hold for Phase 3 studies of tolebrutinib, the independent data monitoring committee (iDMC) overseeing the clinical trials recommended that all studies should pause recruitment globally. Although multiple Health Authorities outside the U.S. have permitted the tolebrutinib studies to continue following the adjustments to the protocol that reduce enrollment of patients with preexisting liver risk factors, Sanofi will respect the iDMC’s recommendation and will pause recruitment globally for those trials still undergoing active recruitment, HERCULES for non-relapsing secondary progressive MS (nrSPMS), PERSEUS for primary progressive MS (PPMS) and URSA for myasthenia gravis (MG). Sanofi’s decision is not based on any new safety findings since implementation of the FDA’s partial clinical hold at the end of June. Further, in alignment with the iDMC recommendation, all participants currently receiving tolebrutinib in all studies will continue on treatment according to the trial protocols.
John Reed, M.D., Ph.D.
Global Head of Research and Development at Sanofi
“Patient safety remains our top priority as we continue to investigate the impact of tolebrutinib on liver function during this recruitment pause. We remain confident in the future of tolebrutinib as a potentially transformative oral treatment option for people living with MS and are working closely with regulatory authorities in order to resume active recruitment within Q4 2022.”
Sanofi is committed to providing the FDA with the requested information by the end of September 2022.
